Trial · NCT07901374

Genicular Nerve Radiofrequency Ablation Versus Hyaluronic Acid Injection for Knee Osteoarthritis Pain

NCT07901374, Not applicable, Not yet recruiting, Hospital Universitari Joan XXIII de Tarragona.

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Genicular Nerve Radiofrequency Ablation Versus Hyaluronic Acid Injection for Knee Osteoarthritis Pain. Trials, record NCT07901374. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901374

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Genicular Nerve Radiofrequency Ablation Versus Hyaluronic Acid Injection for Knee Osteoarthritis Pain
NCT number: NCT07901374
Status: Not yet recruiting
Phases: Not applicable
Enrollment: 70 participants, estimated
Lead sponsor: Hospital Universitari Joan XXIII de Tarragona.
Conditions: Knee Osteoarthritis, Chronic Knee Pain
Interventions: Thermal Radiofrequency Ablation of the Genicular Nerves, Intra-articular Hyaluronic Acid
First posted: 2026-10-28
Last updated: 2026-10-28

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Knee Pain During Movement (Visual Analogue Scale)	Baseline, 1, 3, 6 and 12 months after the intervention	Pain during movement (walking or climbing stairs) in the index knee, measured on a 100 mm visual analogue scale and recorded in cm with one decimal (0 = no pain, 10 = worst imaginable pain). Higher scores indicate worse pain.
Secondary	Change in Knee Pain at Rest (Visual Analogue Scale)	Baseline, 1, 3, 6 and 12 months after the intervention	Pain at rest in the index knee, measured on a 100 mm visual analogue scale and recorded in cm with one decimal (0 = no pain, 10 = worst imaginable pain). Higher scores indicate worse pain.
Secondary	Change in Knee Function (WOMAC)	Baseline, 1, 3, 6 and 12 months after the intervention	Western Ontario and McMaster Universities Osteoarthritis Index (Likert 3.1). Total score 0-96 and subscales for pain (0-20), stiffness (0-8) and physical function (0-68). Higher scores indicate worse symptoms and function.
Secondary	Proportion of Participants Achieving the Minimal Clinically Important Difference in Pain	1, 3, 6 and 12 months after the intervention	Percentage of participants with a reduction of at least 2 points from baseline in pain during movement (visual analogue scale, 0-10).
Secondary	Analgesic Consumption	Baseline, 1, 3, 6 and 12 months after the intervention	Number of days with analgesic use in the previous 4 weeks (0-28) and most potent analgesic used (none, paracetamol, NSAID, weak opioid, strong opioid).
Secondary	Number of Participants With Adverse Events	Up to 12 months after the intervention	Adverse events related to the diagnostic block, radiofrequency ablation or hyaluronic acid injection, systematically recorded at each visit.
Secondary	Retreatment or Rescue Treatment	Up to 12 months after the intervention	Proportion of participants requiring retreatment, rescue treatment (including corticosteroid injection) or indication of total knee arthroplasty, and time to first retreatment or rescue treatment.
Secondary	Health-Related Quality of Life (EQ-5D-5L)	Baseline, 6 and 12 months after the intervention	EQ-5D-5L descriptive system (5 dimensions, 5 levels; utility index calculated with the Spanish value set, where 1 = full health and higher values indicate better health) and EQ-VAS (0-100, higher scores indicate better health).
Secondary	Rate of Negative Diagnostic Genicular Nerve Blocks	4 hours after the diagnostic block	Percentage of participants allocated to the radiofrequency arm with less than 50% pain reduction within 4 hours after the diagnostic block, who therefore do not receive radiofrequency ablation.
Secondary	Patient Global Assessment	Baseline, 1, 3, 6 and 12 months after the intervention	Patient global assessment of the impact of knee osteoarthritis, measured on a 100 mm visual analogue scale (0 = very well, 100 = very poor). Higher scores indicate worse status.

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07901374

GET https://conductscience.org/api/trials/v1/NCT07901374/registered

API reference For AI assistants